BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 16912529)

  • 1. [Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer].
    Ohshima T; Yamada R; Hatori S; Kunisaki C; Makino T; Yamazaki Y; Suda T; Rino Y; Takanashi Y; Imada T
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1105-10. PubMed ID: 16912529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital].
    Abe S; Kojima M; Tamura H; Kurihara H; Kitago M; Kobayashi T; Nakamura T; Ogihara T
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):963-70. PubMed ID: 12894711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical study of TS-1 for inoperative and recurrent gastric cancer and evaluation of long survival cases].
    Tanabe K; Yoshida K; Hamai Y; Ukon K; Ohta K; Hihara J; Toge T
    Gan To Kagaku Ryoho; 2005 Aug; 32(8):1145-8. PubMed ID: 16121917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of advanced gastric cancer effectively treated by TS-1 for 4 years].
    Ogino H; Misawa T; Nasu T; Ihara Y; Kubo S; Sadamoto Y; Harada N; Nakamura K
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):833-6. PubMed ID: 15984526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of treatment of far advanced and recurrent stomach cancer with TS-1].
    Johira H; Yunoki S; Kawata N; Watanabe N; Hachisuka Y; Kimura M; Uomoto M; Hatano H; Sanada E; Watanabe R; Ohmori K; Miyata N
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):195-9. PubMed ID: 15751632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of advanced gastric cancer successfully treated with TS-1/CDDP combination chemotherapy, able to maintain CR for more than two years against multiple liver metastases].
    Meguro E; Kimura T; Noda Y; Matsumoto Y; Irinoda T; Hayakawa Y; Kobayashi M; Takagane A; Hioki J
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):249-52. PubMed ID: 17301537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of TS-1 combined with cisplatin for neoadjuvant chemotherapy in patients with advanced gastric cancer].
    Yabusaki H; Nashimoto A; Tanaka O
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1933-40. PubMed ID: 14650962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study of S-1 for advanced gastric cancer after reduction surgery].
    Inaba Y; Hayashi K; Miura T; Moriya T; Takiguchi M; Isobe H; Watabe S
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1053-7. PubMed ID: 17637541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer].
    Nimura H; Mitsumori N; Tsukagoshi S; Nakajima M; Atomi Y; Suzuki S; Kusano M; Yoshiyuki T; Tokunaga A
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1289-96. PubMed ID: 14518408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy].
    Hatori S; Kunisaki C; Ono H; Sato T; Otsuka Y; Yamada R; Ohshima T; Rino Y; Imada T
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1257-60. PubMed ID: 16969021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination].
    Inaba Y; Watabe S; Ohe S; Kamio Y; Koyama M; Hayashi K; Chiba M
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):239-44. PubMed ID: 11865630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Low-dose paclitaxel therapy as second-line chemotherapy for patients who previously received TS-1 therapy].
    Takemura M; Osugi H; Lee S; Kaneko M; Tanaka Y; Fujiwara Y; Nishizawa S; Iwasaki H
    Gan To Kagaku Ryoho; 2004 Dec; 31(13):2183-6. PubMed ID: 15628768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A phase I study of combination chemotherapy using TS-1 and pirarubicin (THP) for advanced gastric cancer].
    Yamamura Y; Kodera Y; Tanemura H; Oshita H; Miyashita K; Fujimura T;
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):361-5. PubMed ID: 15045941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of advanced gastric cancer resected after successful treatment with the novel oral anticancer drug TS-1].
    Koyama M; Inaba Y; Watabe S; Hayashi K; Tsuge T; Kamio Y; Chiba M; Tamura M
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):531-5. PubMed ID: 12722688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
    Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
    Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of advanced gastric cancer with multiple liver metastases successfully treated with TS-1 and CDDP].
    Tsukahara A; Kaneko K; Tanaka S
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2039-41. PubMed ID: 15570936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of TS-1 therapy for inoperable and recurrent gastric cancer].
    Moriwaki T; Hyodo I; Nishina T; Kajiwara T; Tsuzuki T; Hirao K; Nakauchi M; Nasu J; Hirasaki S; Endo H; Masumoto T; Tanimizu M; Kubo Y; Kurita A
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):489-94. PubMed ID: 12722679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation, including QOL of TS-1 for patients with locally advanced or recurrent gastric cancer at ambulatory setting].
    Oeda M; Hirabayashi N; Takiyama W; Nagamine I; Ohara M; Oshita A; Satou Y; Saeki S; Kirihara Y; Mukaida H; Hisamatu K
    Gan To Kagaku Ryoho; 2003 Oct; 30(10):1453-8. PubMed ID: 14584277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Two cases of advanced pancreatic cancer with cervical lymph node or liver metastasis responding well to S-1 monotherapy].
    Funakoshi A; Senju T; Sumii T
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1505-9. PubMed ID: 17033248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new regimen for TS-1 therapy designed to minimize adverse reactions by introducing a one-week interval after each two-week dosing session].
    Kimura Y; Kikkawa N; Iijima S; Kato T; Naoi Y; Hayashi T; Tanigawa T; Yamamoto H; Kurokawa E
    Gan To Kagaku Ryoho; 2002 Aug; 29(8):1403-9. PubMed ID: 12214468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.